Inflammation in Atherosclerosis - Prof. Dr. Peter Libby (Boston, MA)

Peter Libby, MD, cardiovascular specialist at Brigham and Women’s Hospital (BWH) in Boston, Massachusetts, explains the pathological role of inflammation in atherosclerotic cardiovascular disease (ASCVD), and discusses why antiinflammation treatment may become a novel treatment strategy in affected patients.
Dr. Libby holds the Mallinckrodt Professorship of Medicine at Harvard Medical School; he was the Chief of Cardiovascular Medicine at BWH from 1998 - 2014.
Dr. Libby’s major research focus is the role of inflammation in vascular diseases such as atherosclerosis. He instigated and conducted landmark clinical trials, including the large scale Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) that provided clinical validation of the role of inflammation in atherosclerosis.
Dr. Libby was Editor-in Chief of the current 12th Edition of Braunwald’s Heart Disease, and main author of Harrison’s Principles of Internal Medicine, which are arguably the most renown textbooks in cardiology and internal medicine.
The interview was recorded on July 20th, 2023.
Moderators: Prof. Marcus Säemann (Vienna, Austria), Prof. Stephan Schirmer (Kaiserslautern, Germany), Prof. Florian Custodis (Saarbrücken, Germany) and Prof. Dr. Gunnar Heine (Frankfurt / Homburg, Germany).
Articles discussed:
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group.
N Engl J Med. 2017 doi: 10.1056/NEJMoa1707914
TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial.
Svensson EC, Madar A, Campbell CD, He Y, Sultan M, Healey ML, Xu H, D'Aco K, Fernandez A, Wache-Mainier C, Libby P, Ridker PM, Beste MT, Basson CT.
JAMA Cardiol. 2022 doi: 10.1001/jamacardio.2022.0386
The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis.
Fidler TP, Xue C, Yalcinkaya M, Hardaway B, Abramowicz S, Xiao T, Liu W, Thomas DG, Hajebrahimi MA, Pircher J, Silvestre-Roig C, Kotini AG, Luchsinger LL, Wei Y, Westerterp M, Snoeck HW, Papapetrou EP, Schulz C, Massberg S, Soehnlein O, Ebert B, Levine RL, Reilly MP, Libby P, Wang N, Tall AR.
Nature. 2021 doi: 10.1038/s41586-021-03341-5
Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease
Zhao TX, …, Mallat Z
NEJM Evid 2022 DOI: 10.1056/EVIDoa2100009
Low-dose interleukin 2 for the reduction of vascular inflammation in acute coronary syndromes (IVORY): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trial.
Sriranjan R, Zhao TX, Tarkin J, Hubsch A, Helmy J, Vamvaka E, Jalaludeen N, Bond S, Hoole SP, Knott P, Buckenham S, Warnes V, Bird N, Cheow H, Templin H, Cacciottolo P, Rudd JHF, Mallat Z, Cheriyan J.
BMJ Open. 2022 doi: 10.1136/bmjopen-2022-062602
Music in the Credits:
Klaviersonate Nr. 32 in c-moll, op. 111 - II. Arietta Adagio molto, semplice e cantabile
Ludwig van Beethoven / Artur Schnabel
archive.org/details/beethoven...